Paul Nguyen, MD
Addiction Medicine · Las Vegas, NVNPI 1740497346
Payments from drug & device makers
Across 834 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Otsuka America Pharmaceutical, Inc.$3K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$951
- Supernus Pharmaceuticals, Inc.$759
- plus $3K from 16 others
What the payments were for
- Food & beverage$13,993100%
- Education$550%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 188 | $2,908 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 143 | $2,866 |
| Otsuka America Pharmaceutical, Inc. | 165 | $2,510 |
| Alkermes, Inc. | 63 | $1,239 |
| Neurocrine Biosciences, Inc. | 61 | $951 |
| Supernus Pharmaceuticals, Inc. | 72 | $759 |
| Sunovion Pharmaceuticals Inc. | 24 | $464 |
| Johnson & Johnson | 25 | $444 |
| Teva Pharmaceuticals USA, Inc. | 20 | $392 |
| Vanda Pharmaceuticals Inc. | 15 | $349 |
| Almatica Pharma LLC | 12 | $252 |
| Lundbeck LLC | 12 | $205 |
| Axsome Therapeutics, Inc. | 7 | $150 |
| Eisai Inc. | 7 | $146 |
| Bausch Health US, LLC | 6 | $140 |
| Indivior Inc. | 5 | $109 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Avion Pharmaceuticals | 2 | $30 |
| Neuronetics, Inc. | 1 | $30 |
| Corium, LLC | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$229
How this compares
Too few addiction medicine providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 111 | $182,880 |
| IngrezzaValbenazine Tosylate | 22 | $169,767 |
| Abilify MaintenaAripiprazole | 56 | $146,539 |
| VraylarCariprazine Hcl | 89 | $144,215 |
| RexultiBrexpiprazole | 87 | $127,791 |
| FanaptIloperidone | 41 | $115,602 |
| Invega SustennaPaliperidone Palmitate | 38 | $79,074 |
| Lurasidone Hcl | 96 | $22,419 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $20,771 |
| RisperdalRisperidone | 12 | $10,543 |
| Aripiprazole | 176 | $10,050 |
| Fluphenazine Hcl | 38 | $6,976 |
| Quetiapine Fumarate | 543 | $5,940 |
| Oxcarbazepine | 170 | $5,930 |
| Trazodone Hcl | 703 | $5,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $2,510 | $274,330143 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,866 | $182,880111 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $951 | $169,76722 claims |
| AbbVieVraylar | $2,908 | $144,21589 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $349 | $115,60241 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal, Concerta | $444 | $94,39362 claims |
| Alkermes, Inc.Lybalvi | $1,239 | $20,77114 claims |
| Almatica Pharma LLCSertraline Hcl | $252 | $1,499371 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction medicine providers in Nevadaon file to place this against a meaningful peer group, so we don't.
Other addiction medicine in Las Vegas
- Warren SeedsLas Vegas$7K
- Muhammad HyderLas Vegas$2K
- Michael LevyLas Vegas$588
- Ozoemena AkahLas Vegas$14
- Charlene LetchfordReno$449
- Ryan LeyReno$385
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.